Delisting risk, souring relations are hurdles for Chinese biotech firms seeking to enter US market, analyst says
Scott Moore of the School of Arts & Sciences comments on a growing number of Chinese firms find their American depositary receipts under threat from regulators.
・ From South China Morning Post